NCPA disputes 'bogus' PCMA study
NCPA has issued a sharply worded statement disputing a PCMA study that asserted that the Community Pharmacy Fairness Act of 2007 would increase Medicare Part D drug costs nearly $30 billion over five years. The act, which was introduced in the House of Representatives and has 124 cosponsors, would allow independent pharmacies to negotiate collectively with PBMs.
NCPA has issued a sharply worded statement disputing a PCMA study that asserted that the Community Pharmacy Fairness Act of 2007 would increase Medicare Part D drug costs nearly $30 billion over five years. The act, which was introduced in the House of Representatives and has 124 cosponsors, would allow independent pharmacies to negotiate collectively with PBMs. The PCMA study asserts that "current PBM practices reduce costs while leaving independent pharmacies profitable." According to NCPA CEO Bruce Roberts, "The report's figures are nothing more than an attempt by PBMs to put Congress and the public on notice that they intend to hold American taxpayers hostage if attempts are made to reform the PBMs' anticompetitive business practices."
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
